SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?
The answer remains, ambiguously, “the future,” but at STAT’s Breakthrough Summit leaders from NVIDIA and Google insisted that the impact of AI is visible today.
Kimberly Powell, vice president of healthcare for NVIDIA, pointed to an increase in investigational new drug applications filed with the Food and Drug Administration that cite AI, as well as an uptick in early-stage readouts from clinical trials, as evidence of progress. Some of the recent readouts, Powell said, show that what’s going into Phase 1 clinical trials is more successful.
Click this link for the original source of this article.
Author: Katherine MacPhail and Mario Aguilar
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.